Pfizer Inc. (PFE) — closed signal from January 4, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on April 4, 2026.
Predicted vs. what happened
What happened
Reached its target in 86 days.
The thesis — published January 4, 2026
Pfizer looks like a stock where selling may be running out of steam: price indicators and heavy trading suggest sellers are finishing and many investors still feel positive. The company generates lots of cash and pays nearly all of it as dividends, which can help limit how far the price falls. Sales guidance shows modest decline, so any rise is likely a short-term rebound rather than a big revaluation. We still need a clear sign that downward pressure has ended before fully committing.
Primary drivers
- Price looks oversold and heavy trading hints selling is easing
- Dividend safety talk can keep a floor under the share price
- Low valuation argues the stock could bounce back toward fairer levels
- Further upside depends on the price trend stopping its decline
How it played out
PFE: target reached in 86 days
Lyra published PFE at $25.18 on 2026-01-04 with expected growth of 12%. The thesis pointed to an oversold price, heavy trading that hinted selling was easing, dividend safety talk, low valuation, and the need for the price trend to stop its decline.
Inside the window, PFE reached a peak of $28.75 on 2026-04-02, with a peak gain of 14.2%. That was above the $28.20 target. The target was reached in 86 days. The stock ended at $28.32 on 2026-04-04, also above the target. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.